TCM
IBB icon

TD Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

TD Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12
Closed -$1K – 228
2017
Q3 		$1K Buy
+12
New +$1.28K ﹤0.01% 240

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TD Capital Management's IBB Position: Q4 2017 in Review

TD Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2017, closing a stake of 12 shares — an estimated $1K sold.

TD Capital Management first reported a position in IBB in Q3 2017 and held it in 1 quarter. The position peaked at $1K in Q3 2017. 624 funds tracked by Wall St. Rank hold IBB as of Q4 2017.

  • TD Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2017 after selling out during the quarter.
  • TD Capital Management sold 12 iShares Biotechnology ETF shares in Q4 2017, an estimated $1K.
  • TD Capital Management first reported a position in iShares Biotechnology ETF in Q3 2017 and held it in 1 quarter.
  • TD Capital Management's iShares Biotechnology ETF position peaked at $1K in Q3 2017.
  • 624 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2017.

Based on TD Capital Management's 13F filing for Q4 2017, filed 9 Feb 2018.